Atrieflimmer og hjerneslag

Tidsskrift for den Norske Laegeforening

Volumn 133, Issue 14, 2013, Pages 1453-1457

  Aamodt, Anne Hege ^a   Sandset, Per Morten ^a,b   Atar, Dan ^b,c   Tveit, Arnljot ^d   Russell, David ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Bærum sykehus ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; METHODOLOGY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84884386570     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.12.0850     Document Type: Article

References (36)

1. Schnabel RB. Can we predict the occurrence of atrial fibrillation? Clin Cardiol 2012; 35 (suppl 1): 5-9.
2. Stefansdottir H, Aspelund T, Gudnason V et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace 2011; 13: 1110-7.
3. Tveit A, Abdelnoor M, Enger S et al. Atrial fibrillation and antithrombotic therapy in a 75-year-old population. Cardiology 2008; 109: 258-62.
4. Tveit A. Atrieflimmer i Norge. Hjerteforum 2011; nr. 3: 10-4.
5. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413.
6. Guyatt GH, Akl EA, Crowther M et al. Executive summary: antithrombotic therapy and prevention of thrombosis. 9. utg. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (suppl 2): 7S-47S.
7. Skanes AC, Healey JS, Cairns JA et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012; 28: 125-36.
8. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013; 34: 1041-9.
9. Botto GL, Padeletti L, Santini M et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20: 241-8.
10. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 2012; 43: 265-70.
11. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012; 11: 1066-81.
12. Hannon N, Sheehan O, Kelly L et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010; 29: 43-9.
13. Toni D, Ahmed N, Anzini A et al. Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR. Neurology 2012; 78: 880-7.
14. Tu HT, Campbell BC, Christensen S et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010; 30: 389-95.
15. Healey JS, Connolly SJ, Gold MR et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-9.
16. Suissa L, Lachaud S, Mahagne MH. Optimal timing and duration of continuous electrocardiographic monitoring for detecting atrial fibrillation in stroke patients. J Stroke Cerebrovasc Dis 2012. [Epub ahead of print].
17. Sinha AM, Diener HC, Morillo CA et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J 2010; 160: 36-41.e1.
18. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
19. Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med 2013; 126: 289-96.
20. Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-40.
21. Baker WL, Cios DA, Sander SD et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-52.
22. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
23. Dentali F, Riva N, Crowther M et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-91.
24. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
25. Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-63.
26. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
27. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-94.
28. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
29. Lansberg MG, O'Donnell MJ, Khatri P et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis. 9. utg. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl2): e601S-36S.
30. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12.
31. Sanák D, Herzig R, Král M et al. Is atrial fibrillation associated with poor outcome after thrombolysis? J Neurol 2010; 257: 999-1003.
32. Matute MC, Masjuan J, Egido JA et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 2012; 33: 231-9.
33. Helsedirektoratet. Informasjon om de nye perorale antikoagulasjonsmidlene dabigatran, rivaroksaban og apiksaban. Nasjonal rådgivende spesialistgruppe innen antikoagulasjon. Oslo: Helsedirektoratet, 2013. http://www.helsedirektoratet.no/publikasjoner/informasjon-om-de-nye-peroraleantikoagulasjonsmidlene-dabigatranrivaroksaban-og-apiksaban/Publikasjoner/67338%20Helse%20IS-2050%20Informasjon-8k.pdf (14.5.2013).
34. Chimowitz MI. Endovascular treatment for acute ischemic stroke-still unproven. N Engl J Med 2013; 368: 952-5.
35. Helsedirektoratet. Behandling og rehabilitering ved hjerneslag. IS-1688. Oslo: Helsedirektoratet, 2010. http://helsedirektoratet.no/publikasjoner/nasjonal-retningslinje-for-behandling-ogrehabilitering-ved-hjerneslag-fullversjon/Publikasjoner/nasjonal-retningslinje-forbehandling-og-rehabilitering-ved-hjerneslagfullversjon. pdf (14.5.2013).
36. Statens legemiddelverk. Dabigatran (Pradaxa) skal ikke brukes hos pasienter med kunstige hjerteklaffer. 10.1.2013. http://slv.no/Nyheter/Bivirkninger/Sider/Dabigatran-(Pradaxa)-skalikke-brukes-hos-pasienter-med-kunstige-hjerteklaffer. aspx (21.5.2013).